Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Lai J, Wang H, Peng J, Chen P, Pan Z. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy. Cancer Manag Res. 2018;10:2347–2356. doi:10.2147/CMAR.S17112930122984
   PubMed Web of Science ®Google Scholar
• Esbah O, Oksuzoglu B. Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. Indian J Med Res. 2017;146(5):563–571. doi:10.4103/ijmr.IJMR_1354_1729512598
   PubMedGoogle Scholar
• Li P, Dong J, Zhou X, et al. Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer. Onco Targets Ther. 2017;10:5711–5718. doi:10.2147/OTT.S14797429238203
   PubMed Web of Science ®Google Scholar
• Petekkaya I, Unlu O, Roach EC, et al. Prognostic role of inflammatory biomarkers in metastatic breast cancer. J BUON. 2017;22(3):614–622.28730765
   PubMed Web of Science ®Google Scholar
• Kong Y, Lyu N, Wu J, et al. Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. J Cancer. 2018;9(20):3728–3735. doi:10.7150/jca.2803230405844
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell. 2008;134(5):703–707. doi:10.1016/j.cell.2008.08.02118775299
   PubMed Web of Science ®Google Scholar
• Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S. Lactic dehydrogenase and cancer: an overview. Front Biosci (Landmark Ed). 2015;20:1234–1249.25961554
   PubMed Web of Science ®Google Scholar
• Jia Z, Zhang J, Wang Z, et al. An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. Oncotarget. 2018;9(12):10714–10722. doi:10.18632/oncotarget.2424629535837
   PubMedGoogle Scholar
• Namikawa T, Ishida N, Tsuda S, et al. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer. Gastric Cancer. 2018. doi:10.1007/s10120-018-0897-8
   Web of Science ®Google Scholar
• Ma L, Qiu J, Zhang Y, et al. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. Onco Targets Ther. 2018;11:2533–2543. doi:10.2147/OTT.S15050229765232
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin‘s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin‘s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM1993093032914028141877
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206. doi:10.1200/JCO.2009.23.479919917835
   PubMed Web of Science ®Google Scholar
• Chen B, Dai D, Tang H, et al. Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J Cancer. 2016;7(15):2309–2316. doi:10.7150/jca.1662227994669
   PubMed Web of Science ®Google Scholar
• Liu X, Meng QH, Ye Y, Hildebrandt MA, Gu J, Wu X. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis. 2015;36(2):243–248. doi:10.1093/carcin/bgu24725524924
   PubMed Web of Science ®Google Scholar
• Petekkaya I, Aksoy S, Roach EC, et al. Impact of inflammatory markers on the prognosis of patients with operable breast cancer. J BUON. 2014;19(3):673–680.25261651
   PubMed Web of Science ®Google Scholar
• Bidard FC, Hajage D, Bachelot T, et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 2012;14(1):R29. doi:10.1186/bcr316922330883
   PubMed Web of Science ®Google Scholar
• Brunetto AT, Sarker D, Papadatos-Pastos D, et al. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer. 2010;103(5):607–612. doi:10.1038/sj.bjc.660581220664586
   PubMed Web of Science ®Google Scholar
• Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008;14(1):62–68. doi:10.1097/PPO.0b013e3181629a7b18303485
   PubMed Web of Science ®Google Scholar
• Pierga JY, Asselain B, Jouve M, et al. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer. 2001;91(6):1079–1089.11267952
   PubMed Web of Science ®Google Scholar
• Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol. 2001;12(1):81–87.11249054
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998;16(7):2401–2408. doi:10.1200/JCO.1998.16.7.24019667257
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2011 Available from http://handbook.cochrane.org. Accessed December 5, 2018.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–437.16549855
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.9921604
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-1617555582
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.55712958120
   PubMed Web of Science ®Google Scholar
• Nieder C, Dalhaug A, Pawinski A, Mannsaker B, Haukland E. Survival after palliative radiotherapy in patients with breast cancer and bone-only metastases. In Vivo. 2016;30(6):879–883.27815475
   PubMed Web of Science ®Google Scholar
• Agrawal A, Gandhe MB, Gupta D, Reddy MV. Preliminary study on serum lactate dehydrogenase (LDH)-prognostic biomarker in carcinoma breast. J Clin Diagn Res. 2016;10(3):BC06–BC08. doi:10.7860/JCDR/2016/17111.7364
   PubMed Web of Science ®Google Scholar
• Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015;136(9):2158–2165. doi:10.1002/ijc.2926525307450
   PubMed Web of Science ®Google Scholar
• Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012;18(22):6348–6355. doi:10.1158/1078-0432.CCR-12-139722952345
   PubMed Web of Science ®Google Scholar
• Nisman B, Barak V, Hubert A, et al. Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res. 2003;23(2C):1939–1942.12820483
   PubMed Web of Science ®Google Scholar
• Baur M, Schlappack O, Havelec L, Wrba F, Dittrich C. Prognostic significance of liver metastases as first site of generalisation in patients with breast cancer-a retrospective analysis. Acta Med Austriaca. 2001;28(5):135–140.11774775
   PubMedGoogle Scholar
• Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat. 1997;45(2):181–192.9342443
   PubMed Web of Science ®Google Scholar
• Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23(3):618–624. doi:10.1093/annonc/mdr26321642515
   PubMed Web of Science ®Google Scholar
• Li B, Li C, Guo M, et al. Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. Onco Targets Ther. 2018;11:6287–6294. doi:10.2147/OTT.S17156630310292
   PubMed Web of Science ®Google Scholar
• Chen Z, Guo Q, Lu T, et al. Pretreatment serum lactate dehydrogenase level as an independent prognostic factor of nasopharyngeal carcinoma in the intensity-modulated radiation therapy era. Med Sci Monit. 2017;23:437–445.28120819
   PubMed Web of Science ®Google Scholar
• Zhu L, Li X, Shen Y, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Onco Targets Ther. 2016;9:4879–4886. doi:10.2147/OTT.S10727927540301
   PubMed Web of Science ®Google Scholar
• Biswas S, Lunec J, Bartlett K. Non-glucose metabolism in cancer cells – is it all in the fat? Cancer Metastasis Rev. 2012;31(3–4):689–698. doi:10.1007/s10555-012-9384-622706846
   PubMed Web of Science ®Google Scholar
• Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353–363. doi:10.3233/CBM-16033628582845
   PubMed Web of Science ®Google Scholar
• Di Stefano G, Manerba M, Di Ianni L, Fiume L. Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment. Future Med Chem. 2016;8(6):713–725. doi:10.4155/fmc.16.1027054686
   PubMed Web of Science ®Google Scholar
• Mishra S, Sharma DC, Sharma P. Studies of biochemical parameters in breast cancer with and without metastasis. Indian J Clin Biochem. 2004;19(1):71–75. doi:10.1007/BF0287239423105431
   PubMedGoogle Scholar